Physician profile
Peter J Kourlas
NPI 1700882818
$2,087.44
in general payments reported to CMS, 2019-2025
10 companies · $19.16 in 2025
The $19.16 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $100 · 2020: $410 · 2021: $19.99 · 2022: $21.00 · 2023: $117 · 2024: $1,400 · 2025: $19.16.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $1,400 · Food and Beverage: $136.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $1,400.00 |
| Food and Beverage | $136.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Occlutech US LLC | $1,400.00 | 2024 | |
| Athenex Pharmaceutical Division, LLC | $350.00 | 2020 | |
| Genentech USA, INC. | $117.22 | 2023 | Lunsumio |
| Comsort, INC | $100.00 | 2019 | |
| Exelixis INC. | $44.15 | 2020 | |
| Pfizer INC. | $21.00 | 2022 | |
| Kite Pharma, INC. | $19.99 | 2021 | |
| Abbvie INC. | $19.16 | 2025 | |
| Mckesson Specialty Care Distribution, LLC | $15.92 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$54,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Kourlas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.